96 related articles for article (PubMed ID: 25687901)
1. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
[TBL] [Abstract][Full Text] [Related]
2. A case of severe relapsing sulphonylurea-induced hypoglycaemia.
Mifsud S; Schembri EL; Fava S
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31796456
[TBL] [Abstract][Full Text] [Related]
3. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Lee JY; Jang SY; Nam CM; Kang ES
Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
[TBL] [Abstract][Full Text] [Related]
4. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis.
Evans JM; Ogston SA; Reimann F; Gribble FM; Morris AD; Pearson ER
Diabetes Obes Metab; 2008 Apr; 10(4):350-2. PubMed ID: 18093208
[TBL] [Abstract][Full Text] [Related]
5. Glimepiride Use is Associated with Reduced Cardiovascular Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure: A Prospective Cohort Study.
He W; Yuan G; Han Y; Yan Y; Li G; Zhao C; Shen J; Jiang X; Chen C; Ni L; Wang DW
Eur J Prev Cardiol; 2022 Dec; ():. PubMed ID: 36573717
[TBL] [Abstract][Full Text] [Related]
6. Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.
Sahin I; Bakiner O; Demir T; Sari R; Atmaca A
Diabetes Ther; 2024 Jun; ():. PubMed ID: 38935188
[TBL] [Abstract][Full Text] [Related]
7. [Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].
Winkler G
Orv Hetil; 2015 Mar; 156(13):511-5. PubMed ID: 25796278
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Hassan MH; Abd-Allah GM
Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.
Andersen SE; Christensen M
Br J Clin Pharmacol; 2016 Nov; 82(5):1291-1302. PubMed ID: 27426428
[TBL] [Abstract][Full Text] [Related]
10. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
11. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
Marx N; Rosenstock J; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Espeland MA; Bluhmki E; Mattheus M; Ryckaert B; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Chan SP; Colagiuri S
Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
[TBL] [Abstract][Full Text] [Related]
13. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
[TBL] [Abstract][Full Text] [Related]
15. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
Deacon CF; Lebovitz HE
Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
[TBL] [Abstract][Full Text] [Related]
17. Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.
Joy NG; Tate DB; Davis SN
Metabolism; 2015 Jun; 64(6):729-37. PubMed ID: 25765720
[TBL] [Abstract][Full Text] [Related]
18. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
Rustenbeck I
Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
[TBL] [Abstract][Full Text] [Related]
19. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.
Kalra S; Aamir AH; Raza A; Das AK; Azad Khan AK; Shrestha D; Qureshi MF; Md Fariduddin ; Pathan MF; Jawad F; Bhattarai J; Tandon N; Somasundaram N; Katulanda P; Sahay R; Dhungel S; Bajaj S; Chowdhury S; Ghosh S; Madhu SV; Ahmed T; Bulughapitiya U
Indian J Endocrinol Metab; 2015; 19(5):577-96. PubMed ID: 26425465
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
